Biochemical and pharmacogenetic dissection of human steroid 5α-reductase type II

Pharmacogenetics

Volumn 10, Issue 5, 2000, Pages 407-413

  Makridakis, Nick M ^a   Di Salle, Enrico ^b   Reichardt, Juergen K V ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Discovery Research Oncology   (Italy)

Author keywords

Androgen metabolism; Pharmacogenetic variation; SNP (single nucleotide polymorphism)

Indexed keywords

ANDROSTANOLONE; DUTASTERIDE; FINASTERIDE; N [2,2,2 TRIFLUORO 1 PHENYL 1 (TRIFLUOROMETHYL)ETHYL] 3 OXO 4 AZA 5ALPHA ANDROST 1 ENE 17BETA CARBOXAMIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; STEROID 5ALPHA REDUCTASE; TESTOSTERONE;

AMINO ACID SUBSTITUTION; ARTICLE; CHROMOSOME 2P; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PURIFICATION; HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; PROSTATE DISEASE;

AMINO ACID SUBSTITUTION; BINDING, COMPETITIVE; DNA MUTATIONAL ANALYSIS; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; MALE; MUTATION, MISSENSE; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTEIN BINDING; TESTOSTERONE 5-ALPHA-REDUCTASE;

TRIFLUORO;

EID: 0033936410     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200007000-00004     Document Type: Article

References (14)

1. di Salle E, Giudici D, Radice A, Zaccheo T, Ornati G, Nesi M, et al. PNU 157706, a novel dual type I and II 5alpha-reductase inhibitor. J Steroid Biochem Mol Biol 1998; 64:179-186.
2. Frye SV, Bramson HN, Hermann DJ, Lee FW, Sinhababu AK, Tian G. Discovery and development of GG745, a potent inhibitor of both isozymes of 5 alpha-reductase. Pharm Biotechnol 1998; 11:393-422.
3. Makridakis N, Ross RK, Pike MC, Chang L. Stanczyk FZ, Kolonel LN, et al. A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase. Cancer Res 1997; 57:1020-1022.
4. Makridakis NM, Ross RK. Pike MC, Crocitto LE, Kolonel LN, Pearce CL, et al. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 1999; 354:975-978.
5. Ross RK, Pike MC, Coetzee GA, Reichardt JK, Yu MC, Feigelson H, et al. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res 1998; 58:4497-4504.
6. Russell DW, Wilson JD. Steroid 5 alpha-reductase: two genes/two enzymes. Annu Rev Biochem 1994; 63:25-61.
7. Sinnecker GH, Hiort O, Dibbelt L, Albers N, Dorr HG, Hauss H, et al. Phenotypic classification of male pseudohermaphroditism due to steroid 5 alpha-reductase 2 deficiency. Am J Med Genet 1996; 63:223-230.
8. Stoner E. 5Alpha-reductase inhibitors/finasteride. Prostate 1996; 6:82-87.
9. Syvanen AC, Landegren U, Isaksson A, Gyllensten U, Brookes A. First International SNP Meeting at Skokloster, Sweden, August 1998. Enthusiasm mixed with scepticism about single-nucleotide polymorphism markers for dissecting complex disorders. Eur J Hum Genet 1999; 7:98-100.
10. Thigpen AE, Davis DL, Milatovich A, Mendonca BB, Imperato-McGinley J. Griffin JE, et al. Molecular genetics of steroid 5 alpha-reductase 2 deficiency. J Clin Invest 1992; 90:799-809.
11. Thompson IM, Coltman CA Jr. Crowley J. Chemoprevention of prostate cancer: the prostate cancer prevention trial. Prostate 1997; 33:217-221.
12. Wang M, Bhattacharyya AK, Taylor MF. Tai HH, Collins DC. Site-directed mutagenesis of the NADPH-binding binding domain of rat steroid 5alpha-reductase (isozyme-1) i: analysis of aromatic and hydroxylated amino acid residues. Steroids 1999; 64:356-362.
13. Wigley WC, Prihoda JS. Mowszowicz I, Mendonca BB, New MI, Wilson JD, Russell DW. Natural mutagenesis study of the human steroid 5 alpha-reductase 2 isozyme. Biochemistry 1994; 33:1265-1267.
14. Zaccheo T, Giudici D, di Salle E. Effect of the dual 5alpha-reductase inhibitor PNU 157706 on the growth of Dunning R3327 prostatic carcinoma in the rat. J Steroid Biochem Mol. Biol 1998; 64:193-198.